Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesBeOne Medicines AG

BeOne Medicines AG

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
419.98 USD -4.02 ( 0.95%)
Last update at 2026-11-11T21:03:00Z
VOLUME
436801
Market Cap
39196.83M
P/E
61.99

Momentum Score

…

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
415.93
Low
421.57
High
52 Week Price Range
253.95
Low
385.22
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

BeiGene develops and commercializes oncology therapies globally, with operations in China and the U.S. Long-term growth drivers include sales of marketed cancer medicines, progress in a diversified late-stage pipeline, and scaling international commercial capabilities, which may support revenue diversification.
Material risks are clinical or regulatory setbacks, intense competition and pricing pressure, high R&D and commercialization costs that could suppress profitability, and execution risk in international expansion.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
424.00
Dividend Yield
-
Revenue TTM
6128.96M
Revenue Per Share
55.27
Gross Profit TTM
5448.29M
Debt / Equity
0.46
ROE
14.66%
Net Debt
-2547.72M
ROCE
7.47%
Diluted EPS TTM
5.59

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 416.85M -533.00M -825.84M -1961.04M -1438.59M
Minority interest - - - 0.00M 0.00M
Net income 286.93M -644.79M -881.71M -2003.82M -1457.82M
Selling general administrative 2081.49M 1831.06M 1508.00M 1278.60M 990.12M
Gross profit 4674.49M 3216.15M 2078.86M 1129.45M 1011.38M
Reconciled depreciation 141.69M 171.76M 87.67M 66.28M 46.46M
Ebit 475.09M -533.00M -825.84M -1961.04M -1438.59M
Ebitda 616.77M -361.24M -738.16M -1894.76M -1392.13M
Depreciation and amortization 141.69M 171.76M 87.67M 66.28M 46.46M
Operating income 447.14M -568.20M -1207.74M -1789.66M -1438.73M
Other operating expenses 4895.90M 4378.44M 3666.51M 3205.59M 2615.02M
Interest expense 58.23M 21.80M 4.36M 52.48M -
Tax provision 129.92M 111.78M 55.87M 42.78M 19.23M
Interest income 70.50M 47.84M 74.01M 52.48M -
Net interest income 12.27M 47.84M 74.01M 52.48M -15.76M
Income tax expense 129.92M 111.78M 55.87M 42.78M 19.23M
Total revenue 5343.03M 3810.24M 2458.78M 1415.92M 1176.28M
Total operating expenses 4227.36M 3784.35M 3286.59M 2919.11M 2450.11M
Cost of revenue 668.54M 594.09M 379.92M 286.48M 164.91M
Total other income expense net -30.28M 35.20M 381.90M -171.37M 0.15M
Net income from continuing ops 286.93M -644.79M -881.71M -2003.82M -1457.82M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 8188.57M 5920.91M 5805.27M 6379.29M 8535.52M
Intangible assets 62.70M 129.76M 108.86M 94.57M 103.35M
Other current assets 190.97M 160.09M 219.61M 190.93M 253.44M
Total liab 3827.38M 2588.69M 2267.95M 1995.93M 2402.96M
Total stockholder equity 4361.19M 3332.22M 3537.33M 4383.35M 6132.56M
Other current liab 1173.46M 879.96M 731.65M 562.87M 633.20M
Common stock 0.14M 0.14M 0.14M 0.14M 0.13M
Capital stock 0.14M 0.14M 0.14M 0.14M 0.13M
Retained earnings -8319.90M -8606.84M -7962.05M -7080.34M -5076.53M
Good will - - - 0.11M 0.11M
Other assets - - - 819.89M -
Cash 4547.53M 2627.41M 3171.80M 3869.56M 4375.68M
Total current liabilities 1828.83M 2214.90M 1810.11M 1468.53M 1599.56M
Current deferred revenue - - - 213.86M 187.41M
Net debt -2547.72M -1547.54M -2241.61M -3272.89M -3681.03M
Short term debt 134.71M 869.11M 710.32M 353.01M 449.49M
Short long term debt 57.29M 851.53M 688.37M 328.97M 427.56M
Short long term debt total 1999.81M 1079.87M 930.18M 596.67M 694.64M
Other stockholder equity 12759.19M 12087.91M 11598.69M 11540.98M 11191.01M
Total current assets 6233.59M 3991.59M 4203.41M 5207.08M 7613.88M
Long term investments 61.68M 128.93M 89.64M 91.78M 100.79M
Short term investments - - 2.60M 665.25M 2241.96M
Net receivables 886.86M 709.11M 395.89M 198.98M 500.18M
Long term debt 961.91M 166.48M 197.62M 209.15M 202.11M
Inventory 608.23M 494.99M 416.12M 282.35M 242.63M
Accounts payable 479.04M 405.00M 315.11M 294.78M 262.40M
Accumulated other comprehensive income -78.18M -148.99M -99.45M -77.42M 17.95M
Non currrent assets other 19.91M 13.38M 31.57M 61.89M -55.53M
Non current assets total 1954.98M 1929.32M 1601.86M 1172.21M 921.64M
Capital lease obligations 73.64M 61.85M 44.20M 58.56M 64.97M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -8.39M -548.35M 60.00M 1077.12M 640.66M
Total cashflows from investing activities -276.15M -548.35M 60.00M 1077.12M 640.66M
Net borrowings 3.80M 145.08M 360.77M -65.94M 101.53M
Total cash from financing activities 1059.45M 193.45M 416.48M -18.97M 3636.91M
Net income 286.93M -644.79M -881.71M -2003.82M -1413.35M
Change in cash 1970.90M -547.24M -689.05M -507.85M 2992.88M
Begin period cash flow 2638.75M 3185.98M 3875.04M 4382.89M 1390.01M
End period cash flow 4609.65M 2638.75M 3185.98M 3875.04M 4382.89M
Total cash from operating activities 1127.58M -140.63M -1157.45M -1496.62M -1298.72M
Issuance of capital stock - - 0.00M 0.00M 3442.62M
Depreciation 141.69M 171.76M 87.67M 66.28M 46.46M
Other cashflows from investing activities -81.93M -39.34M -36.44M 1402.56M -51.91M
Change to inventory -93.17M -91.50M -140.95M -56.69M -153.33M
Change to account receivables -164.95M -329.44M -188.31M 304.11M -423.02M
Other cashflows from financing activities -27.06M 48.37M 55.71M 46.96M 92.76M
Capital expenditures 185.84M 529.14M 596.26M 469.10M 314.85M
Change in working capital 191.40M -157.17M -370.54M 132.39M -118.34M
Stock based compensation 510.86M 441.62M 367.62M 303.16M 240.71M
Other non cash items -12.77M 21.96M -361.19M 3.31M -13.11M
Free cash flow 941.74M -669.77M -1753.71M -1965.72M -1613.57M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ONC
BeOne Medicines AG		 -4.02
0.95%		 419.98 61.99 34.13 6.40 7.74 6.07 32.69
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

BeOne Medicines AG

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

94 Aeschengraben 27, Basel, Switzerland, 4051

41 61 685 19 00

https://beonemedicines.com

12000

Name Title Year Born
Mr. John V. Oyler Co-Founder, Executive Chairman & CEO 1968
Mr. Wang Lai Ph.D. President and Global Head of Research & Development 1977
Dr. Xiaodong Wang Ph.D. Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder 1963
Mr. Aaron Rosenberg Chief Financial Officer 1977
Mr. Chan Lee General Counsel, Senior VP & Corporate Secretary 1968
Mr. Titus B. Ball VP & Chief Accounting Officer 1974
Mr. Marcello Damiani Chief Technology Officer 1970
Ms. Liza Heapes Head of Investor Relations NA
Ms. Eleanor Duff Ph.D. Senior VP & Head of Corporate Communications NA
Mr. Graham Hardiman Global Head of Human Resources NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…